Details for Patent: 10,774,085

Which drugs does patent 10,774,085 protect, and when does it expire?

Patent 10,774,085 protects VITRAKVI and is included in two NDAs.

This patent has one hundred and thirteen patent family members in thirty-nine countries.

Summary for Patent: 10,774,085

Title:	Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Abstract:	Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
Inventor(s):	Julia Haas, Steven W. Andrews, Yutong Jiang, Gan Zhang
Assignee:	Array Biopharma Inc
Application Number:	US16/044,653
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 10,774,085

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-001	Nov 26, 2018		RX	Yes	No	10,774,085					METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes	10,774,085					METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes	10,774,085					METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

International Family Members for US Patent 10,774,085

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3106463		301033	Netherlands
European Patent Office	3106463		PA2020504	Lithuania
European Patent Office	3106463		CA 2020 00013	Denmark
European Patent Office	3106463		122020000012	Germany
European Patent Office	3106463		LUC00150	Luxembourg